Tango Therapeutics (TNGX) Competitors $1.61 +0.07 (+4.55%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.62 +0.01 (+0.87%) As of 03/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNGX vs. BCAX, LENZ, ABCL, CRON, PRTA, AVBP, ORGO, CVAC, GHRS, and NUVBShould you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include Bicara Therapeutics (BCAX), LENZ Therapeutics (LENZ), AbCellera Biologics (ABCL), Cronos Group (CRON), Prothena (PRTA), ArriVent BioPharma (AVBP), Organogenesis (ORGO), CureVac (CVAC), GH Research (GHRS), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry. Tango Therapeutics vs. Bicara Therapeutics LENZ Therapeutics AbCellera Biologics Cronos Group Prothena ArriVent BioPharma Organogenesis CureVac GH Research Nuvation Bio Bicara Therapeutics (NASDAQ:BCAX) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, community ranking, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Does the MarketBeat Community believe in BCAX or TNGX? Tango Therapeutics received 15 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 73.68% of users gave Tango Therapeutics an outperform vote. CompanyUnderperformOutperformBicara TherapeuticsOutperform Votes13100.00% Underperform VotesNo VotesTango TherapeuticsOutperform Votes2873.68% Underperform Votes1026.32% Which has better valuation & earnings, BCAX or TNGX? Bicara Therapeutics has higher earnings, but lower revenue than Tango Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/AN/AN/AN/ATango Therapeutics$42.07M4.14-$101.74M-$1.21-1.33 Do institutionals & insiders have more ownership in BCAX or TNGX? 79.0% of Tango Therapeutics shares are owned by institutional investors. 6.3% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to BCAX or TNGX? In the previous week, Bicara Therapeutics had 6 more articles in the media than Tango Therapeutics. MarketBeat recorded 10 mentions for Bicara Therapeutics and 4 mentions for Tango Therapeutics. Bicara Therapeutics' average media sentiment score of 0.25 beat Tango Therapeutics' score of 0.22 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BCAX or TNGX more profitable? Bicara Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -284.42%. Bicara Therapeutics' return on equity of 0.00% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A N/A N/A Tango Therapeutics -284.42%-49.64%-32.00% Do analysts rate BCAX or TNGX? Bicara Therapeutics presently has a consensus target price of $36.50, suggesting a potential upside of 172.40%. Tango Therapeutics has a consensus target price of $12.33, suggesting a potential upside of 666.05%. Given Tango Therapeutics' higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Bicara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBicara Therapeutics beats Tango Therapeutics on 8 of the 13 factors compared between the two stocks. Remove Ads Get Tango Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNGX vs. The Competition Export to ExcelMetricTango TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$174.05M$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E Ratio-1.367.2023.1419.03Price / Sales4.14226.01385.7893.17Price / CashN/A65.6738.1634.64Price / Book0.656.476.934.33Net Income-$101.74M$141.90M$3.20B$247.06M7 Day Performance-8.52%-3.20%-2.30%-0.37%1 Month Performance-22.22%-5.64%2.86%-3.85%1 Year Performance-79.72%-7.47%10.66%1.27% Tango Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNGXTango Therapeutics1.8308 of 5 stars$1.61+4.5%$12.33+666.0%-79.1%$174.05M$42.07M-1.3690Short Interest ↑BCAXBicara TherapeuticsN/A$13.80+4.2%$36.50+164.5%N/A$750.94MN/A0.0032Earnings ReportUpcoming EarningsAnalyst ForecastNews CoverageLENZLENZ Therapeutics1.7628 of 5 stars$26.66+0.6%$41.67+56.3%+21.6%$733.18MN/A-5.59110ABCLAbCellera Biologics2.4747 of 5 stars$2.59+6.1%$7.00+170.3%-47.4%$727.09M$28.83M-4.25500Positive NewsCRONCronos Group1.9068 of 5 stars$1.88+5.0%$3.00+59.6%-32.2%$719.16M$117.62M-14.46450PRTAProthena3.3429 of 5 stars$13.34+2.9%$55.00+312.3%-48.3%$718.05M$135.16M-5.80130Analyst RevisionNews CoveragePositive NewsAVBPArriVent BioPharma1.4346 of 5 stars$20.21+3.5%$39.00+93.0%+3.2%$687.46MN/A-7.8640ORGOOrganogenesis3.5813 of 5 stars$5.42+11.1%$5.50+1.5%+69.2%$687.41M$482.04M-90.33950CVACCureVac3.9857 of 5 stars$3.00+3.8%$10.00+233.3%-8.2%$671.64M$543.28M5.45880News CoverageGHRSGH Research2.5021 of 5 stars$12.88+3.0%$30.86+139.6%+14.4%$670.12MN/A-16.3010NUVBNuvation Bio2.0445 of 5 stars$1.96+3.4%$8.33+326.3%-52.7%$662.12M$7.87M-0.9060Analyst Forecast Remove Ads Related Companies and Tools Related Companies BCAX Competitors LENZ Competitors ABCL Competitors CRON Competitors PRTA Competitors AVBP Competitors ORGO Competitors CVAC Competitors GHRS Competitors NUVB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNGX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
